SWKH News and Press, SWK Holdings Corporation From 03/26/21

TORONTO, March 26, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today announced that it has entered into an amended agreement related to its existing credit facility with SWK Funding LLC (“...

Sincerus Pharmaceuticals Completes Financing With SWK To Support The Demand For Its Customized Dermatologic Medicines PR Newswire POMPANO BEACH, Fla. , March 24, 2021 /PRNewswire/ -- Sincerus Pharmaceuticals, the parent company of Prescriber's Choice and Sin...

Enteris BioPharma Announces Dr. Gary Shangold to Host Webinar on Utilization of 505(b)(2) Regulatory Pathway in Drug Development PR Newswire BOONTON, N.J. , March 16, 2021 /PRNewswire/ -- Enteris BioPharma, Inc. , a biotechnology company developing innovative...

Enteris BioPharma to Host Webinar on Strategies for Initiating Phase 1 Clinical Development with Limited API PR Newswire BOONTON, N.J. , Jan. 12, 2021 /PRNewswire/ -- Enteris BioPharma, Inc. , a biotechnology company developing innovative drug products built ...

Biotechnology company Enteris BioPharma, wholly owned subsidiary of SWK Holdings ([[SWKH]] +0.2%), forecasts growth opportunities this year and says that it will actively pursue partnership discussions with companies seeking US domestic CDMO capabilities.Will advance activities...

Enteris BioPharma Highlights 2020 Achievements and 2021 Outlook Enteris poised to capitalize on multiple value building opportunities involving Peptelligence® and ProPerma™ platforms PR Newswire BOONTON, N.J. , Jan. 7, 2021 /PRNewswire/ -- ...

Flowonix Medical, Inc. and SWK Holdings Corporation Announce Closing of $33 Million Financing PR Newswire MOUNT OLIVE, N.J. , Jan. 4, 2021 /PRNewswire/ -- Flowonix Medical, Inc., a medical device company focused on providing advanced, implantable drug delive...

SWK Holdings' (SWKH) wholly-owned subsidiary, Enteris BioPharma received a second milestone payment of $2.5M from Cara Therapeutics (CARA) with regards the license agreement for Peptelligence oral formulation technology utilized in Oral KORSUVA.According to the contractual splits ag...

SWK Holdings' Subsidiary, Enteris BioPharma, Receives Second Milestone Payment from Cara Therapeutics Second milestone payment related to the development of Oral KORSUVA™ follows initial $2.5 million milestone payment received in October PR Newswire DALLAS ...

EyePoint Pharmaceuticals (EYPT) announces a royalty monetization agreement with SWK Holdings (SWKH) for royalties payable to EYPT under its license agreement with Alimera Sciences (ALIM) for ILUVIEN.EyePoint has received a one-time $16.5M payment from SWK and, in return, SWK is entitled to re...